PFE — Q2 2026 Financial Report Analysis

A $4.3 billion writedown turned a decent operating quarter into a GAAP loss

Pfizer's revenue grew for the second straight quarter, but the company still reported a net loss of $248 million for the three months ended June 28, 2026, against net income of $2,910 million a year earlier. Almost none of that swing came from the underlying drug business. It came from a $4.3 billion writedown of research assets Pfizer had acquired, a $842 million legal charge, and the fact that both landed in the same quarter.

Strip those out and the picture is flat-to-slightly-better: adjusted diluted earnings per share — the company's own non-GAAP measure, which excludes impairments, restructuring and amortization of acquired intangibles — was $0.77 versus $0.78, and adjusted income was $4,440 million versus $4,434 million. The operating business did roughly what it did last year while the balance sheet took the hit.

Operating margin is derived: revenues less cost of sales, selling/informational/administrative expense, R&D, acquired in-process R&D, amortization of intangibles and restructuring charges. Pfizer does not report an operating income subtotal, and it books impairments, legal charges and investment gains below that line in "Other (income)/deductions—net," so the derived figure above excludes all three. Gross margin is revenue minus cost of sales, divided by revenue — the share of each sales dollar left after manufacturing the product.

What the $4.3 billion writedown actually was

Two separate assets were written off, both in the Biopharma segment (Note 4):

• $3.8 billion of in-process R&D for sigvotatug vedotin, a cancer drug candidate that came with the 2023 Seagen acquisition, written off after "unfavorable clinical trial results" in a Phase 3 study for second-line metastatic non-squamous non-small cell lung cancer. In-process R&D is the accounting value assigned to a drug candidate bought as part of an acquisition; when the science fails, the value is written to zero. This is the Seagen deal's bill coming due on one specific program — not a mark against Padcev or Adcetris, which are performing (below).
• $525 million for Oxbryta, a sickle-cell drug pulled from the market in 2024. After engaging with the FDA in July 2026, Pfizer concluded "there was no viable pathway to return Oxbryta to the market in the U.S." That is a formal close-out of an option Pfizer had been holding open, not new news about the drug's safety.

Both are non-cash: the cash was spent years ago at acquisition. What they do is confirm that the acquisition-led pipeline rebuild has a real failure rate, and the $3.8 billion is a large single number by any standard.

The offset almost nobody is quoting: a $1.87 billion ViiV gain

Working the other way inside the same "Other (income)/deductions—net" line was a net gain of $1,870 million from selling Pfizer's stake in ViiV Healthcare, the HIV joint venture. Without it, the quarter's pre-tax loss would have been roughly $2.5 billion rather than $653 million. Two things follow. First, the headline loss understates how bad the impairment quarter was, because a one-time gain partly masked it. Second, the ViiV stake was also generating dividend income — $98 million in this quarter alone, $180 million year-to-date — and that income stream is now gone from future quarters.

Rounding out the line: legal charges of $842 million (versus $422 million), mostly product liability, and a $255 million increase in the fair value of contingent consideration — the estimated cost of milestone payments Pfizer owes if acquired drug candidates hit their targets, chiefly the Metsera contingent value rights.

The tax line looks strange for the same reason. Pfizer recorded a $407 million tax benefit on a pre-tax loss, an effective rate of 62.4% versus 4.6% a year ago, which the filing attributes to "changes in the jurisdictional mix of earnings, primarily due to intangible asset impairments" — the writedowns happened in high-tax jurisdictions, so they generated an outsized tax shield.

The product mix: COVID is nearly finished shrinking, and that is the good news

Revenue rose $381 million, but only $164 million of that (+1%) was operational — a favorable currency move contributed $217 million. Currency was more than half the reported growth, so the "3% growth" headline overstates the business's own progress.

The more useful cut is what happened underneath. COVID-19 products fell $526 million year over year, to $282 million combined:

Because total revenue still rose $381 million while COVID products shed $526 million, everything else grew roughly $900 million — about 6.6% reported, or 5% operationally on the company's own stated basis. Paxlovid at $21 million globally (and zero in the U.S., against $328 million a year ago) is effectively at its floor; a product that small can no longer drag the group down much further. That is the single most important structural fact in the quarter.

On the growth side, the causal detail matters:

• Eliquis (+19% operational) is the biggest contributor, but the filing is explicit that it was driven "primarily by higher net price in the U.S. primarily due to pricing dynamics, including lower rebates and channel mix favorability," with demand second. Price-and-rebate-led growth on a drug facing generic entry and price erosion in international markets is lower-quality growth than volume-led growth, and it is harder to repeat.
• Padcev (+23%) is the cleaner story: share gains in first-line advanced urothelial cancer plus launch uptake in cisplatin-ineligible muscle-invasive bladder cancer. And the reported number is understated — the prior-year quarter included a one-time benefit from switching to a U.S. wholesaler distribution model, so the true underlying growth is better than 23%.
• Abrysvo (+43% operational) grew from a small base, and lumpily: U.S. revenue actually fell 46% to $55 million while international rose from $42 million to $153 million. This is a vaccine with seasonal and government-purchase timing, not a smooth quarterly trend.
• Comirnaty (−34% operational) fell for two distinct reasons the filing separates: "a lower favorable adjustment to the returns provision" (an accounting comp — last year's quarter was flattered by releasing a reserve for expected product returns) and genuinely "lower utilization in the U.S. primarily resulting from a narrower recommendation for vaccination." Only the second is a demand signal.

By segment, Biopharma revenue was $14,661 million (+1% operational) and Pfizer CentreOne, the contract manufacturing arm, $373 million (+5% operational). Pfizer's own "launched and acquired products" grouping — the newer portfolio it is betting on to replace COVID and patent-expiry losses — grew 18% operationally.

Margins went the wrong way, for explainable reasons

Gross margin fell 1.4 points to 72.8%. Cost of sales rose $314 million on flat-to-slightly-up revenue, which management attributes to a $130 million unfavorable sales mix shift, $90 million of higher amortization of the step-up in value assigned to acquired inventory (driven by the Oxbryta impairment, so this too is an echo of the writedown), and $60 million of unfavorable currency. Note that currency helped revenue by $217 million and hurt cost of sales by $60 million — a net tailwind, but not as large as the revenue figure alone implies.

R&D rose 13.2% to $2,809 million, "driven primarily by an increase in spending of $240 million... in certain oncology and obesity product candidates, which was anticipated." That is deliberate spending against the Metsera obesity pipeline and the oncology portfolio, and it is the main reason derived operating margin compressed 5.4 points. Selling and administrative expense was essentially flat at $3,411 million, with $70 million of savings in corporate functions offset by cost-program implementation costs and currency — evidence the cost realignment program is holding the line on overhead even as R&D climbs.

One small item worth noting for how it flatters R&D: a June 2026 funding arrangement with Abingworth, under which Pfizer will receive up to $300 million through 2029 to co-fund development of one treatment, reduced reported R&D expense by $26 million this quarter. It is recognized as a contra-expense, not revenue, so it makes R&D look $26 million lower than the underlying spend.

Takeaway: The $4.3 billion impairment is the headline but not the story — it is a non-cash reckoning with one failed Seagen-era asset, and it was two-thirds masked by a one-time $1.87 billion ViiV gain that will not recur. The story is that COVID revenue has fallen to $282 million a quarter and can barely shrink further, while the rest of the portfolio grew about 5% operationally and the newer launched/acquired products grew 18%. Pfizer's post-COVID revenue base is now close to fully re-based; from here the question is whether Eliquis's price-driven growth and the obesity/oncology R&D build can carry it past the patent expiries ahead.

Cash, balance sheet and capital returns

Operating cash flow for the first six months was $3,450 million, nearly double the $1,753 million of the year-ago period. Cash and equivalents stood at $976 million with a further $10,723 million in short-term investments, against long-term debt of $60,495 million (down from $61,641 million at year-end 2025). Deleveraging is the stated priority: Pfizer paid $4.9 billion of dividends in the first half ($0.86 per share) and has repurchased no shares in 2026, with guidance assuming none for the rest of the year despite $3.3 billion of remaining authorization. Dividends are being funded, buybacks are not — a reasonable read is that the balance sheet, not shareholder-return appetite, is setting the constraint.

Guidance and forward view

Pfizer raised full-year 2026 revenue guidance by $500 million at the midpoint, to $60.5–$62.5 billion (from $59.5–$62.5 billion). The composition matters more than the number: non-COVID products are running approximately $1.5 billion better than expected, while COVID product expectations were cut to about $4 billion from about $5 billion. The raise is therefore entirely a non-COVID story, partly given back to a further COVID markdown.

Adjusted diluted EPS guidance was reaffirmed at $2.80–$3.00 — notable because it now absorbs roughly $0.10 of dilution from the Innovent Biologics transaction, a licensing and co-development deal for 12 early-stage cancer programs ($650 million upfront, up to $9.85 billion in milestones) that closed July 10, 2026 and will hit third-quarter results. Reaffirming through a $0.10 headwind is a modest implied raise.

Management also expanded its cost programs after quarter-end: an additional $1.0 billion of net savings in selling and administrative costs from 2027–2029 (bringing the Realigning Our Cost Base program to roughly $6.7 billion since inception, with about $5.1 billion already achieved through 2025), and a second phase of the Manufacturing Optimization Program worth about $1.5 billion through 2029, taking that program to roughly $3.0 billion. The Metsera integration is expected to yield about $600 million of annual synergies by the end of 2026 against approximately $700 million of one-time costs. The filing states plainly that "long-term improvement in gross margin will remain a key focus for the Company over the next few years" — consistent with this quarter's margin slip being a problem management knows it owns.

Our read: the trajectory is better than a GAAP loss suggests, but the quality of the growth is mixed. The COVID drag is essentially spent, which removes the single largest headwind of the last three years, and the 18% operational growth in launched and acquired products is the number to track — it is the direct measure of whether the Seagen and Metsera money is working. Against that, the largest growth contributor this quarter was Eliquis on U.S. price and rebate dynamics rather than volume, which is not durable at that rate; currency provided more than half of reported revenue growth; and the sigvotatug vedotin failure is a reminder that the acquired pipeline carries binary risk that shows up as multi-billion-dollar writedowns. Adjusted EPS down 10% year-to-date ($1.52 versus $1.69) with revenue up 4% is the honest summary of the first half: the top line has stabilized, the earnings base has not yet followed, and the cost programs are what management is counting on to close that gap.